I keep having the same conversation with QA leads at small biotech firms. They walk me through their AI stack. ChatGPT summarizes literature. Claude drafts deviation reports. Copilot suggests CAPA root causes from a batch record.
Each use gets framed as a convenience. What often has not happened is the next question: did that AI output support a regulated decision?
That gap worries me. A firm may think it is using a general chatbot for informal productivity, while the workflow has crossed into validation territory. The line is not crossed when someone buys a validated vendor system. It is crossed when an AI output influences a GxP decision.
The CSA scope question nobody asks
FDA’s Computer Software Assurance logic applies validation expectations to software touching GxP decisions. The primary source I would start from now is FDA’s draft guidance, “Considerations for the Use of Artificial Intelligence to Support Regulatory Decision-Making”. It frames AI used to support regulatory decisions as something that needs defined context of use, credibility of outputs, human accountability, and lifecycle management.
That is not just “the LIMS.” Teams keep treating validation scope as if it lives in a labeled box: LIMS, eQMS, MES, instrument software. Anything outside that box feels informal enough to ignore. AI does not respect that boundary. If an output feeds a decision about whether to release a batch, investigate a deviation, close a CAPA, or trust a document review, it belongs in the scope conversation.
The model does not have to be the final decider. It only has to influence the decision.
Every small biotech I have walked through this realizes within minutes that at least one casual AI use deserves a closer look. The Slack thread where someone pasted a deviation summary and the team used the response to scope the investigation. The Claude draft that became the starting point for a CAPA write-up. The Copilot suggestion a scientist accepted and acted on. None were labeled validation projects, but each can put an unvalidated tool into a regulated chain.
What the warning-letter signal means
ComplianceG reported that on April 2, 2026, the FDA issued a warning letter citing AI misuse as a GxP compliance violation. I have not seen a public FDA warning-letter link for that item, so I would not build an argument on it alone. Treat it as a directional signal that FDA is looking at this boundary, not as confirmed precedent.
Small firms sometimes read this kind of signal and assume it must apply to someone bigger. I do not think that is a safe assumption. CSA logic scales down. A 40-person biotech using ChatGPT to draft deviation reports is not outside the problem. It is inside the problem with fewer controls, fewer logs, and less room to absorb a bad finding.
The validation gap is the work
Once a firm sees the scope, the temptation is to ban casual AI use and call the problem solved. That usually moves the risk instead of removing it. People under deadline pressure still need a faster way to summarize, draft, search, compare, and extract. If no sanctioned path exists, they find one. Now the same data is exposed, the audit trail is gone, and QA has less visibility than before.
I wrote about this dynamic in an earlier post on keeping IP out of AI tools: a ban without a boundary just moves the risk somewhere you cannot see it.
The actual work is drawing the line and writing down the validation story for the uses that stay. Some uses should stop because the GxP decision they feed is too sensitive for an unvalidated model under default vendor terms. Some uses can stay with a documented context of use, an owner, human review, and a log of what touched what and when. Some uses never needed AI in the first place and should go back to a template.
This is not always a six-month evaluation. For a small biotech that has kept the use narrow, the first pass is closer to an inventory and scope decision. Which workflows exist? Which ones touch GxP decisions? Which ones expose regulated or confidential data? Which ones produce output that someone acts on without checking?
For firms that have let AI sprawl for two years across every department, it takes longer because the inventory itself becomes the work. You cannot validate what you have not catalogued.
Where this lands
Every QA lead I have talked to recently has at least one use they already suspect is in scope and have not wanted to inspect closely. The cost of looking is low. The cost of waiting for an audit finding, a customer question, or a warning letter to force the conversation is higher.
The practical move is not panic. It is an inventory, a boundary, and a short validation story for the workflows that remain. If this is the conversation you have been putting off, the AI Workflow Diligence Sprint is a fixed-fee scoping call built to map current AI use against validation scope.